Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
personalized phage cocktails
- Development stage
- Preclinical
- Lead developer
- Tolka AI Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Tolka AI Therapeutics is developing a personalized bacteriophage therapy platform targeting Mycobacterium abscessus complex (MABC) infections, specifically for patients with MABC pulmonary disease (MABC-PD) and nontuberculous mycobacterial (NTM) lung disease. The platform utilizes an AI-driven selection process to identify and customize GMP-grade phage cocktails tailored to the specific bacterial strain isolated from an individual patient. These phages function by specifically infecting and lysing the target bacteria, offering a potential solution for infections that are resistant to conventional antibiotics. The company currently provides access through an Expanded Access Program and is moving toward formal clinical trials to evaluate safety, efficacy, and tolerability.
- Other names
- personalized phage therapyprecision phage cocktailsAI-selected phage cocktails
Beyond the preview
Go deeper on personalized phage cocktails.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on personalized phage cocktails.